Venus Concept stock, medical aesthetic technology

Venus Concept stock reports CEO change effective September 7

Published on 09/25/2026 at 17:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Brad Oliver brings more than 20 years in aesthetic leadership to Venus Concept as CEO. The company reaches over 60 countries and operates in 9 direct markets.

Venus Concept stock,  medical aesthetic technology,  CEO transition,  OTC Markets, Illustration mit AI erstellt.
Venus Concept stock, medical aesthetic technology, CEO transition, OTC Markets, Illustration mit AI erstellt.

Venus Concept stock reports a leadership change effective September 7, 2026, as Brad Oliver takes over as chief executive officer. Venus Concept said on September 9, 2026, that the transition is intended to preserve strategic, operational, and customer-facing continuity.

Brad Oliver takes the helm

Oliver became CEO on September 7, 2026, while Rajiv De Silva moved into a special adviser role. The two executives are working together during the transition, according to Venus Concept.

The incoming CEO brings more than 20 years of leadership experience in the aesthetic industry and most recently served as President and General Manager for the Americas at Lumenis. That background gives the appointment a commercial emphasis as Venus Concept works to expand its medical device business.

Global footprint sets the scale

Venus Concept says it reaches over 60 countries and operates in 9 direct markets. Its portfolio includes Venus Versa, Venus Bliss, Venus Velocity, Venus Viva, Venus Legacy, Venus Epileve, and AI.ME platforms.

The company also markets NeoGraft and the ARTAS iX robotic hair restoration system. This combination gives the new CEO responsibility across both medical aesthetics and hair restoration, rather than a single product category.

OTC status changes the frame

Trading status is a central reference for the security. Robinhood lists Venus Concept as delisted to OTC on February 9, 2026, followed by a pending stock liquidation entry dated April 7, 2026.

The same tracker records a cash merger on April 15, 2026, under which shareholders were set to receive USD 0.0400 per share. Investing.com identifies VERO as trading on OTC Markets, making the corporate-action timeline more relevant than a Nasdaq trading narrative.

Cash merger sets the reference

Venus Concept's documented cash-merger consideration was USD 0.0400 per share on April 15, 2026. The leadership transition on September 7, 2026, therefore arrives after the security's delisting and merger milestones.

Venus Concept stock facts

  • Company: Venus Concept Inc.
  • Ticker: VERO
  • Trading venue: OTC Markets
  • Sector / Industry: Medical aesthetic technology

Disclaimer...

en | boerse | 70184397 |